Skye Bioscience announced the resignation of John P. Sharp as Chief Financial Officer and principal financial accounting officer effective September 8, 2026, citing no disagreements with auditors or management. The Board appointed President and CEO Punit Dhillon to serve concurrently as principal financial accounting officer starting that same date, with his existing compensation terms remaining unchanged. Additionally, the Company received notification from Nasdaq confirming it regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, closing the matter regarding its common stock's trading status. Skye Bioscience operates in the biotechnology industry, focusing on the development of novel therapeutics.
